Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NAPHAZOLINE HYDROCHLORIDE vs VASOCON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
Vasoconstrictor; alpha-1 adrenergic receptor agonist causing smooth muscle contraction in blood vessels, reducing nasal congestion and ocular redness.
Ocular: relief of redness, itching, and irritation due to minor eye irritations or allergic conjunctivitis. Nasal: temporary relief of nasal congestion due to colds, allergies, or sinusitis.
Relief of nasal congestion due to colds, allergies, sinusitis,Ocular decongestant for redness relief
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
Adults: 2 drops of 0.25% solution in each eye every 4 hours as needed.
Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life.
Terminal elimination half-life: 2-3 hours; clinically, repeated doses may be needed for sustained effect in conditions like hypotension.
Not extensively studied; likely hepatic metabolism via unknown enzymes.
Primarily hepatic via monoamine oxidase (MAO) metabolism.
Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine.
Primarily renal (60-80% as unchanged drug and metabolites), with minor biliary/fecal elimination (10-20%).
Not well characterized; expected to be low (<20%) based on structural analogs.
Approximately 75-80%, primarily to albumin.
Not established in humans; based on animal data, approximately 0.5-1.0 L/kg, suggesting distribution into total body water.
0.3-0.5 L/kg; reflects distribution within extracellular fluid and rapid equilibration with tissues.
Ophthalmic and intranasal: low systemic bioavailability due to local vasoconstriction limiting absorption; exact % not determined, estimated <1%.
Intramuscular: 100%; Subcutaneous: 100%; Oral: <5% due to extensive first-pass metabolism.
No dose adjustment required; primarily locally acting with minimal systemic absorption.
No dose adjustment required for renal impairment.
No dose adjustment required; use caution in severe hepatic impairment due to potential for systemic effects.
No dose adjustment required for hepatic impairment.
Children ≥6 years: 1-2 drops of 0.1% ophthalmic solution every 6-8 hours; nasal spray 0.05% for children ≥6 years, 1 spray per nostril every 8-10 hours. Contraindicated in infants and children <6 years due to risk of CNS depression.
Children: 1 drop of 0.125% solution in each eye every 4 hours as needed.
Elderly patients may be more sensitive to adverse effects (e.g., rebound congestion, hypertension); use lowest effective dose and shortest duration. Avoid in patients with cardiovascular disease or glaucoma.
Use caution due to increased risk of adverse effects; consider lower concentration (0.125%) if needed.
None
None
Prolonged use may cause rebound congestion (rhinitis medicamentosa). Use with caution in patients with cardiovascular disease (hypertension, arrhythmias), hyperthyroidism, diabetes, or prostatic hyperplasia. Avoid use in patients with narrow-angle glaucoma. Do not exceed recommended dosage or duration.
Use with caution in hypertension, hyperthyroidism, diabetes, cardiovascular disease, and prostatic hypertrophy. Avoid prolonged use (>3 days nasal, >72 hours ocular) due to rebound congestion. Not recommended in children under 6 years for nasal use.
Hypersensitivity to naphazoline or any component. Narrow-angle glaucoma (ophthalmic use). Use with MAO inhibitors or within 14 days of stopping therapy (risk of hypertensive crisis).
Hypersensitivity to any component, narrow-angle glaucoma, severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, and during pregnancy (first trimester).
No significant food interactions; avoid excessive caffeine or other stimulants as they may potentiate sympathomimetic effects.
No significant food interactions. Avoid excessive caffeine or alcohol as they may exacerbate ocular dryness.
Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks include vasoconstriction and reduced uterine blood flow. No adequate and well-controlled studies in pregnant women. Animal studies have not been reported. First trimester: No known teratogenic effects. Second and third trimesters: Potential risk of reduced uteroplacental perfusion when used systemically; topical use at recommended doses unlikely to cause significant effects. Overall, classified as FDA Pregnancy Category C. Caution is advised.
VASOCON (tetrahydrozoline) ophthalmic. Teratogenic risk: Category C. First trimester: No adequate human studies; animal studies not available. Second/third trimester: Potential maternal hypertension or bradycardia may reduce uteroplacental perfusion. Avoid chronic use.
Excretion in human milk is unknown. Due to low systemic absorption after topical application, amounts ingested by an infant are expected to be minimal. No known adverse effects in nursing infants. M/P ratio not reported. Consider benefit of treatment versus potential risk to infant. Use caution and avoid prolonged or excessive dosing.
No human data on excretion into breast milk; M/P ratio unknown. Systemic absorption minimal after ophthalmic dose. Consider benefit versus theoretical risk of infant vasoconstriction.
No dose adjustments required for topical ocular or nasal use due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not significant for topical administration. Use at standard recommended doses and avoid prolonged or excessive application.
No standard dose adjustment recommended for ophthalmic use. Avoid systemic use due to potential vasoconstriction and hypertension. Use lowest effective dose for shortest duration.
Naphazoline is a direct-acting sympathomimetic with rapid onset; use limited to 3-5 days to avoid rebound congestion and rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma due to potential mydriasis. Caution in cardiovascular disease, hypertension, and hyperthyroidism; may elevate BP and cause palpitations. Not for use in infants or children under 6 years due to risk of CNS depression.
VASOCON (naphazoline/phenylephrine) is an ophthalmic decongestant. Avoid in patients with narrow-angle glaucoma due to risk of angle closure. Rebound hyperemia occurs with prolonged use >72 hours. Systemic absorption may cause hypertension, especially in patients on MAOIs or with cardiovascular disease.
Do not use for more than 3-5 consecutive days to avoid worsening congestion and dependence.,Avoid contact with eyes; if eye contact occurs, flush with water for 15 minutes.,Do not share the bottle with others to prevent infection spread.,Store at room temperature, away from light and moisture.,Consult a doctor before use if you have heart disease, high blood pressure, or an enlarged prostate.
Do not use for more than 72 hours to avoid rebound redness.,Remove contact lenses before instillation; wait 15 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Report eye pain, vision changes, or persistent redness to your doctor.,Avoid use if you have glaucoma or are taking MAO inhibitors.
"Naphazoline, an alpha-1 adrenergic receptor agonist, induces vasoconstriction and elevates blood pressure. Co-administration with ergometrine, an ergot alkaloid that also causes potent vasoconstriction via serotonin and alpha-adrenergic receptor activation, results in additive or synergistic hypertensive effects. This combination significantly increases the risk of severe hypertension, hypertensive crisis, and potential end-organ damage such as stroke or myocardial ischemia."
"Naphazoline, an alpha-adrenergic agonist, can cause systemic vasoconstriction and reflex bradycardia. When combined with nadolol, a non-selective beta-blocker, the bradycardic effects may be additive, leading to an increased risk of atrioventricular (AV) block. This interaction can result in profound bradycardia, hypotension, and potential syncope, particularly in patients with pre-existing cardiac conduction abnormalities."
"Naphazoline, an alpha-adrenergic agonist with vasoconstrictive properties, can increase systemic blood pressure through peripheral vasoconstriction, which may counteract the antihypertensive effects of cyclobenzaprine, a centrally acting muscle relaxant that can lower blood pressure due to its sedative and alpha-blocking activities. This pharmacodynamic opposition may reduce the efficacy of cyclobenzaprine in managing hypertension or lead to inadequate blood pressure control. Clinically, patients may experience elevated blood pressure readings or require dose adjustments of antihypertensive therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NAPHAZOLINE HYDROCHLORIDE vs VASOCON, answered by our medical review team.
NAPHAZOLINE HYDROCHLORIDE is a Ophthalmic Decongestant that works by Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.. VASOCON is a Ophthalmic Decongestant that works by Vasoconstrictor; alpha-1 adrenergic receptor agonist causing smooth muscle contraction in blood vessels, reducing nasal congestion and ocular redness.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NAPHAZOLINE HYDROCHLORIDE and VASOCON depend on the specific clinical indication. These are both Ophthalmic Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NAPHAZOLINE HYDROCHLORIDE is: 1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.. The standard adult dose of VASOCON is: Adults: 2 drops of 0.25% solution in each eye every 4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NAPHAZOLINE HYDROCHLORIDE and VASOCON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NAPHAZOLINE HYDROCHLORIDE is classified as Category C. Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks. VASOCON is classified as Category C. VASOCON (tetrahydrozoline) ophthalmic. Teratogenic risk: Category C. First trimester: No adequate human studies; animal studies not available. Second/third trimester: Potential mat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.